The initial use of AI in life sciences is a passive copilot, like a smarter search bar. The next leap is to 'agentic AI' which proactively closes knowledge gaps, simulates conversations, and provides real-time visibility. This shift is about preparing teams, not just arming them with information.

Instead of trying to anticipate every potential harm, AI regulation should mandate open, internationally consistent audit trails, similar to financial transaction logs. This shifts the focus from pre-approval to post-hoc accountability, allowing regulators and the public to address harms as they emerge.

The traditional government model of setting a regulation and waiting years to assess it is obsolete for AI. A new approach is needed: a dynamic board of government, industry, and academic leaders collaborating to make and update rules in real-time.

Thomas Laffont envisions a future where all work meetings are monitored by AI, not for transcription, but for compliance. The system would provide immediate feedback to an individual for inappropriate behavior, preventing patterns of abuse before they become established and discovered years later.

To manage compliance risk in regulated industries, treat AI agents like new employees. Before deployment, the agent must pass the same knowledge assessment a human would take. This quantifies the risk, turning a 'black box' AI into an observable and testable system with a verifiable accuracy score.

The FDA is abandoning rigid, fixed-length clinical trials for a "continuous" model. Using AI and Bayesian statistics, regulators can monitor data in real-time and approve a drug the moment efficacy is proven, rather than waiting for an arbitrary end date, accelerating access for patients.

Auditing frontier AI models cannot follow a traditional, once-a-year checklist model. Due to rapid development, verifiers must be deeply embedded with labs, working "hip-to-hip" to continuously assess systems from pre-deployment through their entire lifecycle.

MedTech AI companies can speed up regulatory approval by building a trusted, real-time post-market surveillance system. This shifts the burden of proof from pre-market studies to continuous real-world evidence, giving regulators the confidence to approve innovations faster, turning them from blockers into partners.

As AI tools increasingly guide patient diagnosis and treatment recommendations, pharma's focus must shift. The primary challenge is no longer just influencing the HCP directly, but ensuring your product data is structured to "win" in the AI's algorithmic suggestions.